Home/Biosimilar Atlas/Companies/Eli Lilly

Eli Lilly

Biosimilar developer, United States. 1 development product across 1 molecule: insulin glargine.

First approval in the Atlas: Sep 2014, Abasaglar, insulin glargine (EMA)
FDAproducts approved1
EMAproducts approved1
MHRAproducts approved1
PMDAproducts approved1
HCproducts approved1
CDSCOproducts approved1
EDEproducts registered0
Connections
1molecule1product6 of 7markets0candidates in trials6companies on the same molecules

Portfolio by market

MoleculeProductFDAEMAMHRAPMDAHCCDSCOEDEMarkets
Insulin glargineRezvoglar / Abasaglar LY2963016Dec 2021Sep 2014MHRADec 2014Sep 2015Aug 2017ยท6/7

Month shown is the first approval or registration of that product in that market.

Companies on the same molecules

Developers whose portfolios overlap most with Eli Lilly, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.

Biocon BiologicsOne shared molecule: insulin glargine9 molecules in its portfolioCiplaOne shared molecule: insulin glargine1 molecule in its portfolioEris LifesciencesOne shared molecule: insulin glargine2 molecules in its portfolioGan & Lee PharmaceuticalsOne shared molecule: insulin glargine3 molecules in its portfolioGenesys BiologicsOne shared molecule: insulin glargine1 molecule in its portfolioLG ChemOne shared molecule: insulin glargine2 molecules in its portfolio

Chronology

Compare Eli Lilly with other developers on the comparison page.

Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.

Planning your biosimilar strategy?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.